Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM

Biodexa Pharmaceuticals announces an update in respect of its open label Phase 1 study of MTX110 in recurrent glioblastoma. In October 2023, the Company announced completed recruitment of four patients into cohort A of its Phase 1 study of MTX110 in patients with recurrent glioblastoma. MAGIC-G1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery via implanted refillable pump and catheter. Patients received MTX110 via intermittent repeated CED infusions. As of today, the status of patients in Cohort A is as follows: Patients #1 and #2 have deceased with overall survival since start of treatment of 12 months and 13 months, respectively. Patients #3 and #4 remain in post-study follow-up. Patient #3 had progression free survival of six months and OS thus far of 13 months since start of treatment. Patient #4 has not yet had confirmed progression and, as of today, has PFS and OS of 12 months since start of treatment. These interim data in rGBM build on the data announced by the Company on July 2, 2024, and presented at the recent 21st International Symposium on Paediatric Neuro-Oncology of a Phase 1 study of MTX110 in nine patients with Diffuse Midline Glioma which showed, after only two infusions and a single patient at optimum dose, median OS of 16.5 months. In an earlier Phase 1 study conducted by the University of California San Francisco of MTX110 in seven patients with DMG which showed median OS of 26.1 months. These data compare favorably with median OS in a cohort of 316 cases of 10.0 months.